- Home
- SFHG vs TNGX Comparison
SFHG vs TNGX Comparison
Compare SFHG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFHG
- TNGX
- Stock Information
- Founded
- SFHG 1993
- TNGX 2014
- Country
- SFHG Hong Kong
- TNGX United States
- Employees
- SFHG N/A
- TNGX N/A
- Industry
- SFHG Publishing
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- SFHG Consumer Discretionary
- TNGX Health Care
- Exchange
- SFHG Nasdaq
- TNGX Nasdaq
- Market Cap
- SFHG 16.2M
- TNGX 351.2M
- IPO Year
- SFHG 2024
- TNGX N/A
- Fundamental
- Price
- SFHG $0.75
- TNGX $5.02
- Analyst Decision
- SFHG
- TNGX Strong Buy
- Analyst Count
- SFHG 0
- TNGX 6
- Target Price
- SFHG N/A
- TNGX $12.20
- AVG Volume (30 Days)
- SFHG 48.6K
- TNGX 4.0M
- Earning Date
- SFHG 07-11-2025
- TNGX 08-06-2025
- Dividend Yield
- SFHG N/A
- TNGX N/A
- EPS Growth
- SFHG N/A
- TNGX N/A
- EPS
- SFHG N/A
- TNGX N/A
- Revenue
- SFHG $19,760,935.00
- TNGX $40,990,000.00
- Revenue This Year
- SFHG N/A
- TNGX N/A
- Revenue Next Year
- SFHG N/A
- TNGX N/A
- P/E Ratio
- SFHG N/A
- TNGX N/A
- Revenue Growth
- SFHG 30.89
- TNGX 10.09
- 52 Week Low
- SFHG $0.55
- TNGX $1.03
- 52 Week High
- SFHG $24.00
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- SFHG N/A
- TNGX 69.44
- Support Level
- SFHG N/A
- TNGX $4.70
- Resistance Level
- SFHG N/A
- TNGX $5.63
- Average True Range (ATR)
- SFHG 0.00
- TNGX 0.60
- MACD
- SFHG 0.00
- TNGX -0.01
- Stochastic Oscillator
- SFHG 0.00
- TNGX 65.38
About SFHG Samfine Creation Holdings Group Limited Ordinary Share
Samfine Creation Holdings Group Ltd operates through its subsidiaries. It is an established one-stop printing service provider which principally provides printing services in Hong Kong and the PRC. It offers a wide range of printed products such as (i) book products, which mainly include children's books, educational books, art books, notebooks, diaries and journals; and (ii) novelty and packaging products, which mainly include handcraft products, book sets, pop-up books, stationery products, products with assembly parts and other specialized products, shopping bags and package boxes.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.